Terms: = Thyroid cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
5 results:
1. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
2. Elevated TRIP13 drives the akt/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract] [Full Text] [Related]
3. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary thyroid cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract] [Full Text] [Related]
4. Liquid-based FNAC of the thyroid: a 4-year survey with SurePath.
Geers C; Bourgain C
Cancer Cytopathol; 2011 Feb; 119(1):58-67. PubMed ID: 21140482
[TBL] [Abstract] [Full Text] [Related]
5. Molecular biology of thyroid cancer initiation.
Riesco-Eizaguirre G; Santisteban P
Clin Transl Oncol; 2007 Nov; 9(11):686-93. PubMed ID: 18055323
[TBL] [Abstract] [Full Text] [Related]
